51
|
Fushimi K, Kanazawa T, Fujimura A, Kitagawa Y, Hasegawa Y, Doi T. Effect of intentional convection on the passivity of an Fe–6Cr surface in pH 4.5 Na2SO4 solution. Electrochim Acta 2020. [DOI: 10.1016/j.electacta.2020.136237] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
52
|
Doi T, Hirai S, Kaneko M, Ohashi S, Nakajima K, Oguchi F, Kato S, Taniguchi Y, Matsubayashi Y, Hayashi N, Tanaka S, Oshima Y. Bone strength of the proximal femur in healthy subjects with ossification of the posterior longitudinal ligament. Osteoporos Int 2020; 31:757-763. [PMID: 31814062 DOI: 10.1007/s00198-019-05253-7] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/19/2019] [Accepted: 12/01/2019] [Indexed: 10/25/2022]
Abstract
UNLABELLED We compared the bone strength measured via quantitative computed tomography-based finite element method (QCT/FEM) between healthy adults with and without ossification of the posterior longitudinal ligament (OPLL). No statistically significant difference was observed in the bone strength between healthy adults with and without OPLL. Hyperostosis of the posterior longitudinal ligament in OPLL may not be associated with the systemic bone strength. INTRODUCTION Although patients with OPLL have been reportedly associated with increased level of bone mineral density (BMD) using dual-energy X-ray absorptiometry (DXA), little is known about the bone strength in OPLL subjects. The aim of this study is to investigate the bone strength measured via QCT/FEM in healthy subjects with OPLL using the medical check-up data, including whole-body CT scans. METHODS We examined 796 participants (529 men and 267 women) who underwent CT scans in a single health center between January 2008 and May 2009. We identified OPLL in whole spine and divided the subjects into two groups: non-OPLL and OPLL groups. We calculated the predicted bone strength (PBS) of the proximal femur using QCT/FEM and examined the bone mineral status of the calcaneus using quantitative ultrasound (QUS). We compared the PBS and the QUS parameters between the non-OPLL and OPLL groups. RESULTS Seventy-four subjects (9.3%; 57 men and 17 women) were diagnosed with OPLL in the whole spine. The OPLL group was significantly older than the non-OPLL group. No statistically significant difference was observed in the PBS and the QUS parameters between the non-OPLL and OPLL groups in both sexes. Furthermore, no statistically significant difference was noted in the PBS and the QUS parameters between two groups in age- and gender-matched analysis. CONCLUSIONS Our results suggest that hyperostosis of the posterior longitudinal ligament in OPLL may not be associated with bone strength and bone mineral status at the extremities.
Collapse
Affiliation(s)
- T Doi
- Department of Orthopaedic Surgery, University of Tokyo Hospital, 7-3-1 Hongo, Bunkyo-ku, Tokyo, Japan
| | - S Hirai
- Department of Orthopaedic Surgery, University of Tokyo Hospital, 7-3-1 Hongo, Bunkyo-ku, Tokyo, Japan
| | - M Kaneko
- Department of Orthopaedic Surgery, Kanto Rosai Hospital, 1-1 Kizukisumiyoshi-cho, Nakahara-ku, Kawasaki, Kanagawa, Japan
| | - S Ohashi
- Department of Orthopaedic Surgery, National Hospital Organization, Sagamihara Hospital, 18-1 Sakuradai, Minami-ku, Sagamihara, Kanagawa, Japan
| | - K Nakajima
- Department of Orthopaedic Surgery, University of Tokyo Hospital, 7-3-1 Hongo, Bunkyo-ku, Tokyo, Japan
| | - F Oguchi
- Department of Orthopaedic Surgery, University of Tokyo Hospital, 7-3-1 Hongo, Bunkyo-ku, Tokyo, Japan
| | - S Kato
- Department of Orthopaedic Surgery, University of Tokyo Hospital, 7-3-1 Hongo, Bunkyo-ku, Tokyo, Japan
| | - Y Taniguchi
- Department of Orthopaedic Surgery, University of Tokyo Hospital, 7-3-1 Hongo, Bunkyo-ku, Tokyo, Japan
| | - Y Matsubayashi
- Department of Orthopaedic Surgery, University of Tokyo Hospital, 7-3-1 Hongo, Bunkyo-ku, Tokyo, Japan
| | - N Hayashi
- Department of Computational Diagnostic Radiology and Preventive Medicine, The University of Tokyo Hospital, 7-3-1 Hongo, Bunkyo-ku, Tokyo, Japan
| | - S Tanaka
- Department of Orthopaedic Surgery, University of Tokyo Hospital, 7-3-1 Hongo, Bunkyo-ku, Tokyo, Japan
| | - Y Oshima
- Department of Orthopaedic Surgery, University of Tokyo Hospital, 7-3-1 Hongo, Bunkyo-ku, Tokyo, Japan.
| |
Collapse
|
53
|
Hiyama E, Sasaki K, Miyamoto T, Doi T, Hatsuda T, Yamamoto Y, Rijken TA. Possible Lightest Ξ Hypernucleus with Modern ΞN Interactions. Phys Rev Lett 2020; 124:092501. [PMID: 32202898 DOI: 10.1103/physrevlett.124.092501] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/19/2019] [Revised: 01/18/2020] [Accepted: 01/22/2020] [Indexed: 06/10/2023]
Abstract
Experimental evidence exists that the Ξ-nucleus interaction is attractive. We search for NNΞ and NNNΞ bound systems on the basis of the AV8 NN potential combined with either a phenomenological Nijmegen ΞN potential or a first principles HAL QCD ΞN potential. The binding energies of the three-body and four-body systems (below the d+Ξ and ^{3}H/^{3}He+Ξ thresholds, respectively) are calculated by a high precision variational approach, the Gaussian expansion method. Although the two ΞN potentials have significantly different isospin (T) and spin (S) dependence, the NNNΞ system with quantum numbers (T=0, J^{π}=1^{+}) appears to be bound (one deep for Nijmegen and one shallow for HAL QCD) below the ^{3}H/^{3}He+Ξ threshold. Experimental implications for such a state are discussed.
Collapse
Affiliation(s)
- E Hiyama
- Department of Physics, Kyushu University, Fukuoka, Japan, 819-0395 and Strangeness Nuclear Physics Laboratory, RIKEN Nishina Center, Wako 351-0198, Japan
| | - K Sasaki
- Center for Gravitational Physics, Yukawa Institute for Theoretical Physics, Kyoto University, Kyoto 606-8502, Japan
| | - T Miyamoto
- Center for Gravitational Physics, Yukawa Institute for Theoretical Physics, Kyoto University, Kyoto 606-8502, Japan and Quantum Hadron Physics Laboratory, RIKEN Nishina Center, Wako 351-0198, Japan
| | - T Doi
- Quantum Hadron Physics Laboratory, RIKEN Nishina Center, Wako 351-0198, Japan and Interdisciplinary Theoretical and Mathematical Sciences Program (iTHEMS), RIKEN, Wako 351-0198, Japan
| | - T Hatsuda
- Interdisciplinary Theoretical and Mathematical Sciences Program (iTHEMS), RIKEN, Wako 351-0198, Japan and Quantum Hadron Physics Laboratory, RIKEN Nishina Center, Wako 351-0198, Japan
| | - Y Yamamoto
- Physics Section, Tsuru University, Tsuru, Yamanashi 402-8555, Japan and Strangeness Nuclear Physics Laboratory, RIKEN Nishina Center, Wako 351-0198, Japan
| | - Th A Rijken
- Institute for Theoretical Physics, University of Nijmegen, Njjmegen, Netherlands
| |
Collapse
|
54
|
Tsutsumimoto K, Doi T, Nakakubo S, Kim M, Kurita S, Ishii H, Shimada H. Cognitive Frailty as a Risk Factor for Incident Disability During Late Life: A 24-Month Follow-Up Longitudinal Study. J Nutr Health Aging 2020; 24:494-499. [PMID: 32346687 DOI: 10.1007/s12603-020-1365-9] [Citation(s) in RCA: 19] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
Abstract
OBJECTIVES Association between cognitive frailty as identified by a new operational definition and incident disability in the community setting remains unclear. This will be the catalyst for preventive interventions designed to treat adverse health problems among elderlies. DESIGN A 24-month follow-up longitudinal study on a community-based cohort. SETTING Community-setting. PARTICIPANTS Participants included a total of 9,936 older adults aged 65 years or older. MEASUREMENTS Frailty was characterized as slow walking speed or/and muscle weakness represented by grip strength. Cognitive function was assessed according to several tests. Cognitive impairment was defined below the age-education reference threshold. Participants were categorized into the four groups: robust, cognitive impairment alone, frailty alone, and cognitive frailty (both frail and cognitive impairment). Incident disability data was extracted from the Japanese Long-Term Care system. RESULTS The prevalence of cognitive frailty was 11.2%. The cumulative incidence rates of incident disability in each group were also estimated (robust, 9.6/1,000 person-years (95% CI 7.9 to 11.7); cognitive impairment, 21.3/1,000 person years (95% CI 16.3 to 27.7); frailty, 45.4/1,000 person years (95% CI 39.5 to 52.3); and cognitive frailty, 79.9/1,000 person years (95% CI 68.6 to 93.1)). Adjusted Cox proportional hazard model revealed that the cognitive frailty group had the highest hazard ratio (HR 3.86, 95%CI 2.95 - 5.05, P < 0.001). CONCLUSIONS A proper operational definition was developed to determine cognitive frailty among elderlies. Cognitive frailty is more associated with incident disability in community-setting than cognitive impairment or physical frailty alone.
Collapse
Affiliation(s)
- K Tsutsumimoto
- Kota Tsutsumimoto, Section for Health Promotion, Department of Preventive Gerontology, Center for Gerontology and Social Science, National Center for Geriatrics and Gerontology, 7-430, Morioka-cho, Obu City, Aichi Prefecture, 474-8511, Japan, Tel: +81-562-44-5651, Fax: +81-562-46-8294, E-mail:
| | | | | | | | | | | | | |
Collapse
|
55
|
Shimada H, Makizako H, Tsutsumimoto K, Doi T, Lee S, Suzuki T. Cognitive Frailty and Incidence of Dementia in Older Persons. J Prev Alzheimers Dis 2019; 5:42-48. [PMID: 29405232 DOI: 10.14283/jpad.2017.29] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Abstract
BACKGROUND Cognitive frailty may be a preventive or therapeutic target for preventing dementia and functional decline with age. OBJECTIVES To examine the relationship between physical and cognitive frailty and the incidence of dementia in community-living older persons. DESIGN A prospective cohort study. SETTING General community in Japan. PARTICIPANTS A total of 4072 persons aged ≥ 65 years. SETTING A community in Japan. PARTICIPANTS A total of 4072 community-dwelling older persons aged ≥ 65 years participated in the study. MEASUREMENTS We characterized physical frailty as ≥ 3 of the following criteria: slow walking speed, muscle weakness, exhaustion, low physical activity, and weight loss. We used the National Center for Geriatrics and Gerontology-Functional Assessment Tool, which includes tests of word list memory, attention, and executive function, and processing speed to screen for cognitive frailty. The presence of ≥ 2 cognitive impairments, indicated by an age-adjusted score of at least 1.5 standard deviations below the reference threshold, was defined as cognitive frailty. The incidence of dementia was determined using data collected by the Japanese Health Insurance System over 24 months. RESULTS The overall prevalence rates of physical frailty, cognitive impairment, and cognitive frailty (i.e., coexistence of frailty and cognitive impairment) were 5.1%, 5.5%, and 1.1%, respectively. During the follow-up period, 81 participants (2.0%) developed dementia. We found significant relationships between the incidence of dementia and cognitive impairment (hazard ratio (HR): 3.85, 95% confidence interval (95% CI): 2.09-7.10) and cognitive frailty (HR: 6.19, 95% CI: 2.7-13.99). However, the association between dementia and physical frailty did not reach significance (HR: 1.95, 95% CI: 0.97-3.91). CONCLUSIONS Individuals with cognitive frailty had the highest risk of dementia. Future research should implement dementia prevention strategies among older persons with cognitive frailty.
Collapse
Affiliation(s)
- H Shimada
- Hiroyuki Shimada, PhD, Department of Preventive Gerontology, Center for Gerontology and Social Science, National Center for Geriatrics and Gerontology, 7-430 Morioka-cho, Obu City, Aichi Prefecture, 474-8511, Japan, Tel: +81-562-44-5651 (ext. 5611), Fax: +81-562-45-5638, E-mail:
| | | | | | | | | | | |
Collapse
|
56
|
Yamazaki K, Ryoo BY, Doi T, Paik P, Veillon R, Decaens T, Faivre S, Falchook G, Hong D, Scheele J, Bruns R, Berghoff K, Qin S. Pooled safety analysis of tepotinib in Asian patients with advanced solid tumours. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz420.006] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
57
|
Kim SB, Doi T, Kato K, Chen J, Shah M, Adenis A, Luo S, Qin S, Kojima T, Metges JP, Francois E, Muro K, Cheng Y, Li Z, Yuan X, Wang R, Cui Y, Bhagia P, Shen L. KEYNOTE-181: Pembrolizumab vs chemotherapy in patients (pts) with advanced/metastatic adenocarcinoma (AC) or squamous cell carcinoma (SCC) of the esophagus as second-line (2L) therapy. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz422.002] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
58
|
Yunokawa M, Takahashi S, Aoki D, Yonemori K, Hara H, Hasegawa K, Takehara K, Harano K, Nomura H, Noguchi E, Horie K, Ogasawara A, Okame S, Doi T. First-in-human phase I study of TAS-117, an allosteric AKT inhibitor, in patients with advanced solid tumours. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz244.018] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
59
|
Funabashi S, Kataoka Y, Harada-Shiba M, Hori M, Doi T, Ogura M, Hirayama A, Nishikawa R, Tsuda K, Noguchi T, Yasuda S. P938Extensive formation of atherosclerotic cardiovascular disease in subjects with severe familial hypercholesterolemia defined by the international atherosclerosis society criteria. Eur Heart J 2019. [DOI: 10.1093/eurheartj/ehz747.0532] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Introduction
The International Atherosclerosis Society (IAS) has proposed “severe familial hypercholesterolemia (FH)” as a FH phenotype with the highest cardiovascular risk. Coronary artery disease (CAD) represents a major atherosclerotic change in FH patients. Given their higher LDL-C level and atherogenic clinical features, more extensive formation of atherosclerosis cardiovascular disease including not only CAD but stroke/peripheral artery disease (PAD) may more frequently occur in severe FH.
Methods
481 clinically-diagnosed heterozygous FH subjects were analyzed. Severe FH was defined as untreated LDL-C>10.3 mmol/l, LDL-C>8.0 mmol/l+ 1 high-risk feature, LDL-C>4.9 mmol/l + 2 high-risk features or presence of clinical ASCVD according to IAS proposed statement. Cardiac (cardiac death and ACS) and non-cardiac (stroke and peripheral artery disease) events were compared in severe and non-severe FH subjects.
Results
Severe FH was identified in 50.1% of study subjects. They exhibit increased levels of LDL-C and Lipoprotein (a) with a higher frequency of LDLR mutation. Furthermore, a proportion of %LDL-C reduction>50% was greater in severe FH under more lipid-lowering therapy (Table). However, during the observational period (median=6.3 years), severe FH was associated with a 5.9-fold (95% CI, 2.05–25.2; p=0.004) and 5.8-fold (95% CI, 2.02–24.7; p=0.004) greater likelihood of experiencing cardiac-death/ACS and stroke/PAD, respectively (picture). Multivariate analysis demonstrated severe FH as an independent predictor of both cardiac-death/ACS (hazard ratio=3.39, 95% CI=1.12–14.7, p=0.02) and stroke/PAD (hazard ratio=3.38, 95% CI=1.16–14.3, p=0.02) events.
Clinical characteristics of severe FH Non-severe FH Severe FH P-value Baseline LDL-C (mmol/l) 5.3±1.5 6.6±2.0 <0.0001 Lp(a) (mg/dl) 15 [8–28] 21 [10–49] <0.0001 LDLR mutation (%) 49.6% 58.9% 0.00398 On-treatment LDL-C (mmol) 133 [106–165] 135 [103–169] 0.9856 %LDL-C reduction>50% 21.3% 49.8% <0.0001 High-intensity statin (%) 13.3% 42.3% <0.0001 PCSK9 inhibitor (%) 6.3% 21.2% <0.0001
Clinical outcome
Conclusions
Severe FH subjects exhibit substantial atherosclerotic risks for coronary, carotid and peripheral arteries despite lipid lowering therapy. Our finding underscore the screening of systemic arteries and the adoption of further stringent lipid management in severe FH patients.
Collapse
Affiliation(s)
- S Funabashi
- National Cerebral and Cardiovascular Center, Cardiovascular Medicine, Osaka, Japan
| | - Y Kataoka
- National Cerebral and Cardiovascular Center, Cardiovascular Medicine, Osaka, Japan
| | - M Harada-Shiba
- National Cerebral and Cardiovascular Center, Molecular Innovation in Lipidology, Osaka, Japan
| | - M Hori
- National Cerebral and Cardiovascular Center, Molecular Innovation in Lipidology, Osaka, Japan
| | - T Doi
- National Cerebral and Cardiovascular Center, Cardiovascular Medicine, Osaka, Japan
| | - M Ogura
- National Cerebral and Cardiovascular Center, Molecular Innovation in Lipidology, Osaka, Japan
| | - A Hirayama
- National Cerebral and Cardiovascular Center, Cardiovascular Medicine, Osaka, Japan
| | - R Nishikawa
- Sapporo Medical University, Renal and Metabolic Medicine, Sapporo, Japan
| | - K Tsuda
- Osaka Medical College, Cardiology, Takatsuki, Japan
| | - T Noguchi
- National Cerebral and Cardiovascular Center, Cardiovascular Medicine, Osaka, Japan
| | - S Yasuda
- National Cerebral and Cardiovascular Center, Cardiovascular Medicine, Osaka, Japan
| |
Collapse
|
60
|
Minami K, Tanaka Y, Okamoto T, Shimizu N, Doi T, Ogawa H, Hokka D, Jimbo N, Nishio W, Yoshimura M, Itoh T, Maniwa Y. EP1.12-17 Neuroendocrine Marker Staining Pattern Categorization of Small-Sized Pulmonary Large Cell Neuroendocrine Carcinoma. J Thorac Oncol 2019. [DOI: 10.1016/j.jtho.2019.08.2262] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
61
|
Alsina M, Tabernero J, Arkenau HT, Squadroni M, Doi T, Faustino C, Ghidini M, Mansoor W, Shitara K, Van Cutsem E, Causse-Amellal N, Leger C, Skanji D, Ilson D. Efficacy and safety of trifluridine/tipiracil (FTD/TPI) in European patients with heavily pretreated metastatic gastric cancer (mGC): An analysis of the TAGS study. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz247.127] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
62
|
Decaens T, Ryoo BY, Falchook G, Veillon R, Doi T, Yamazaki K, Hong D, Qin S, Scheele J, Bruns R, Berghoff K, Faivre S, Paik P. Safety profile of tepotinib in patients with advanced solid tumors: Pooled analysis of phase I and II data. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz244.041] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
63
|
Mach N, Curigliano G, Santoro A, Kim DW, Tai D, Hodi S, Wilgenhof S, Doi T, Longmire T, Sun H, Xyrafas A, Gutzwiller S, Manenti L, Lin CC. Phase (Ph) II study of MBG453 + spartalizumab in patients (pts) with non-small cell lung cancer (NSCLC) and melanoma pretreated with anti–PD-1/L1 therapy. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz253.028] [Citation(s) in RCA: 16] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
64
|
Tsuda K, Kataoka Y, Nishikawa R, Doi T, Nakashima T, Hosoda H, Honda S, Fujino M, Yoneda S, Otsuka F, Nakao K, Tahara Y, Asaumi Y, Noguchi T, Yasuda S. P1561An elevated risk of heart failure and stroke events in octogenarian Japanese patients with acute myocardial infarction who received percutaneous coronary intervention. Eur Heart J 2019. [DOI: 10.1093/eurheartj/ehz748.0321] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Background
The proportion of the octogenarian population is expanding especially in Eastern society. Due to the clustering of risk factors, acute myocardial infarction (AMI) represents a major cardiovascular complication in octogenarian subjects. This suggests the need to further optimize their therapeutic management to prevent future cardiac events after AMI. However, analysis of clinical characteristics and cardiovascular outcomes in octogenarian subjects with AMI who received the current established medical therapies is limited.
Purpose
To investigate clinical features and prognosis in octogenarian AMI subjects treated with percutaneous coronary intervention (PCI).
Methods
We analyzed 1547 AMI subjects underwent PCI between 2007 and 2017. Baseline characteristics and the occurrence of composite major adverse cardiovascular events (cardiac death, non-fatal MI, revascularization, heart failure and stroke) were compared in octogenarian and non-octogenarian subjects.
Results
22.0% (340/1547) of study subjects was octogenarian. They were more likely to have chronic kidney disease (CKD) and a lower level of LDL-C on admission (Table). Moreover, a higher prevalence of severer Killip class and LVEF <30% were observed in octogenarians (Table). However, they were not optimally treated with the established medical therapies at discharge (Table). During the observational period (median=3.1 years), the composite of cardiovascular events more frequently occurred in octogenarian subjects. Of note, they exhibited a 2.15-fold and 3.01-fold increased risk for heart failure and stroke events, respectively (Figure).
Table 1 Non-Octogenarian (n=1207) Octogenarian (n=340) P-value CKD* (%) 33.8 63.2 <0.0001 LVEF <30% (%) 5.7 10.3 0.02 Killip class 1.33±0.03 1.55±0.05 <0.0001 LDL-C (mmol/L) 3.20±0.03 2.80±0.05 <0.0001 Statin (%) 86.3 78.2 0.0006 Beta-blocker (%) 74.0 65.8 0.005 ACE-I/ARB (%) 87.3 76.6 <0.0001 DAPT (%) 86.0 88.6 0.42 *CKD is defined as estimated glomerular filtration rate (eGFR) <60 ml/min/1.73 m2.
Figure 1
Conclusions
Octogenarian subjects with AMI were high-risk group associated with heart failure and stroke events. Their distinct clinical backgrounds may affect the adoption of optimal medical therapies, potentially resulting in worse cardiovascular outcomes. Further intensified management should be applied to octogenarian subjects with AMI.
Collapse
Affiliation(s)
- K Tsuda
- Osaka Medical College, Department of Cardiology, Takatsuki, Japan
| | - Y Kataoka
- National Cerebral and Cardiovascular Center Hospital, Department of Cardiovascular Medicine, Suita, Osaka, Japan
| | - R Nishikawa
- Sapporo Medical University, Department of Cardiovascular, Renal and Metabolic Medicine, Sapporo, Japan
| | - T Doi
- National Cerebral and Cardiovascular Center Hospital, Department of Cardiovascular Medicine, Suita, Osaka, Japan
| | - T Nakashima
- National Cerebral and Cardiovascular Center Hospital, Department of Cardiovascular Medicine, Suita, Osaka, Japan
| | - H Hosoda
- National Cerebral and Cardiovascular Center Hospital, Department of Cardiovascular Medicine, Suita, Osaka, Japan
| | - S Honda
- National Cerebral and Cardiovascular Center Hospital, Department of Cardiovascular Medicine, Suita, Osaka, Japan
| | - M Fujino
- National Cerebral and Cardiovascular Center Hospital, Department of Cardiovascular Medicine, Suita, Osaka, Japan
| | - S Yoneda
- National Cerebral and Cardiovascular Center Hospital, Department of Cardiovascular Medicine, Suita, Osaka, Japan
| | - F Otsuka
- National Cerebral and Cardiovascular Center Hospital, Department of Cardiovascular Medicine, Suita, Osaka, Japan
| | - K Nakao
- National Cerebral and Cardiovascular Center Hospital, Department of Cardiovascular Medicine, Suita, Osaka, Japan
| | - Y Tahara
- National Cerebral and Cardiovascular Center Hospital, Department of Cardiovascular Medicine, Suita, Osaka, Japan
| | - Y Asaumi
- National Cerebral and Cardiovascular Center Hospital, Department of Cardiovascular Medicine, Suita, Osaka, Japan
| | - T Noguchi
- National Cerebral and Cardiovascular Center Hospital, Department of Cardiovascular Medicine, Suita, Osaka, Japan
| | - S Yasuda
- National Cerebral and Cardiovascular Center Hospital, Department of Cardiovascular Medicine, Suita, Osaka, Japan
| |
Collapse
|
65
|
Metges J, François E, Shah M, Adenis A, Enzinger P, Kojima T, Muro K, Bennouna J, Hsu C, Moriwaki T, Kim S, Lee S, Kato K, Shen L, Qin S, Ferreira P, Wang R, Bhagia P, Kang S, Doi T. The phase 3 KEYNOTE-181 study: pembrolizumab versus chemotherapy as second-line therapy for advanced esophageal cancer. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz154.011] [Citation(s) in RCA: 22] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
66
|
Makino S, Kawamoto C, Ikeda T, Doi T, Narise A, Tanaka T, Almas C, Hannig M, Carvalho R, Sano H. Whitening Efficacy of Chewing Gum Containing Sodium Metaphosphate on Coffee Stain: Placebo-controlled, Double-blind In Situ Examination. Oper Dent 2019; 44:469-475. [PMID: 31172873 DOI: 10.2341/17-385-c] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
Abstract
This study aimed to evaluate the ability of chewing gum containing sodium metaphosphate (SMP) to remove coffee stains from enamel in situ. This was a double-blind (subjects, evaluators), parallel-group, crossover, randomized clinical trial with 30 healthy adult volunteers. Each participant held an appliance with a hydroxyapatite (HA) pellet on the lower lingual side of his or her mouth for two hours to allow pellicle formation. The appliances were subsequently immersed in coffee solution at 37°C for 48 hours. The color of the HA pellet before and after coffee immersion was measured using a spectrophotometer. The participant set the appliance and chewed two pieces of test gum, which contained 7.5 mg of SMP per piece, or control gum without SMP. Each cycle included five minutes of exposure to chewing gum, after which the appliances were placed in 100% relative humidity at room temperature for a 30-minute incubation. This cycle was repeated five times for each gum type. The color of the HA pellet was measured after each chewing cycle using the spectrophotometer. In addition, ΔE* values, which indicate the change in pellet color after each chewing cycle compared with after coffee immersion, were calculated. Data were analyzed using the paired t-test with Bonferroni adjustment to compare ΔE* values of control and test gum after each chewing cycle. The ΔE* values of test gum were significantly higher than those of control gum after all chewing cycles, excluding the first cycle (p<0.05). This finding indicates that test gum containing SMP was more effective at removing coffee stains from the HA pellet than control gum. We conclude that chewing gum containing SMP can effectively remove coffee stains from HA pellets. Thus, SMP is a promising agent to be further explored in tooth-cleaning studies.
Collapse
|
67
|
Nakajima K, Nakata T, Matsuo S, Doi T, Jacobson A. 239Machine learning model for predicting sudden cardiac death and heart failure death using 123I-metaiodobenzylguanidine. Eur Heart J Cardiovasc Imaging 2019. [DOI: 10.1093/ehjci/jez145.003] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Affiliation(s)
- K Nakajima
- Kanazawa University Hospital, Kanazawa, Japan
| | - T Nakata
- Hakodate Goryoukaku Hospital, Hakodate, Japan
| | - S Matsuo
- Kanazawa University Hospital, Kanazawa, Japan
| | - T Doi
- Teine Keijinkai Hospital, Sapporo, Japan
| | - A Jacobson
- Diagram Consulting, Kihei, United States of America
| |
Collapse
|
68
|
Powell CA, Camidge DR, Gemma A, Kusumoto M, Baba T, Kuwano K, Bankier A, Kiura K, Tamura K, Modi S, Tsurutani J, Doi T, Iwata H, Krop IE, Zhang L, Jasmeet S, Saito K, Shahidi J, Yver A, Takahashi S. Abstract P6-17-06: Characterization, monitoring and management of interstitial lung disease in patients with metastatic breast cancer: Analysis of data available from multiple studies of DS-8201a, a HER2-targeted antibody drug conjugate with a topoisomerase I inhibitor payload. Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-p6-17-06] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Several classes of anti-cancer agents including certain immunotherapies, systemic chemotherapies, and targeted therapies including trastuzumab and T-DM1 increase the risk of interstitial lung disease (ILD) and fatal cases have been reported. For DS-8201a, interim efficacy and safety analyses of available data established a final recommended dose of 5.4 mg/kg IV q3wk in advanced HER2-positive breast cancer (BC). Based on preliminary clinical results, ILD was identified as an important risk for DS-8201a. A robust monitoring and management plan was established across all studies and an international, independent ILD adjudication committee (AC) reviews the cases reported as ILD on an ongoing basis.
Methods: All subjects (sbj) who received ≥1 dose of DS-8201a across 7 ongoing studies were included in this analysis. Reported ILD (standardized MedDRA Query terms) included the terms ILD, pneumonitis, and organizing pneumonia. ILD frequencies were calculated based on investigator's assessment and after adjudication. The analysis of potential risk factors associated with ILD is ongoing.
Results: As of 21 June 2018, 448 sbj received ≥1 dose of DS-8201a across multiple tumor types, including BC. Of the 321 sbj with BC, 173 (53.9%) were from Japan, 103 (32.1%) from the US, and 45 (14.0%) from 6 other countries (Spain, South Korea, Taiwan, Belgium, France, and Italy). These sbj received 1 of 7 doses of DS-8201a (0.8 mg/kg: 3 sbjs, 1.6 mg/kg: 1 sbj, 3.2 mg/kg: 3 sbjs, 5.4 mg/kg: 111 sbjs, 6.4 mg/kg: 178 sbj, 7.4 mg/kg: 20 sbj, 8.0 mg/kg: 5 sbj). Overall, 44 cases of potential ILD were reported by the investigators across all tumor types (44/448, 9.8%; Grade ≥3 10/448, 2.2%). In sbj with BC who received 5.4 mg/kg, any grade and Grade ≥3 investigator-reported ILD were 7.2% (8/111) and 0.9% (1/111), respectively. The ILD AC assessed 30 of 44 cases; 22 were considered drug-related ILD, 4 were ILD but not drug-related, and 4 were found not to be ILD. For adjudicated drug-related ILD cases, the median time to onset was 159 (range; 46-591) days from the time of first dose.
Grade 1 Grade 2 Grade 3 Grade 4 Grade 5 All Grades All tumors, All doses (N=448) Investigator-reported20 (4.5)14 (3.1)4 (0.9)1 (0.2)5 (1.1)44 (9.8)Cases adjudicated13840530Adjudicated as drug-related ILD9 (2.0)6 (1.3)3 (0.7)04 (0.9)22 (4.9) BC, All doses (N=321) Investigator-reported17 (5.3)11 (3.4)3 (0.9)1 (0.3)4 (1.2)36 (11.2)Cases adjudicated11830426Adjudicated as drug-related ILD8 (2.5)6 (1.9)3 (0.9)04 (1.2)21 (6.5) BC, 5.4 mg/kg (N=111) Investigator-reported4 (3.6)3 (2.7)001 (0.9)8 (7.2)Cases adjudicated120014Adjudicated as drug-related ILD00001 (0.9)1 (0.9)n (%), except where noted
Conclusions: These analyses confirm that ILD is an important identified risk for DS-8201a. Further analyses are ongoing to better understand the potential risk factors associated with the incidence of on-treatment ILD. When ILD is suspected, early diagnosis through appropriate imaging, laboratory tests, and pulmonary consultation as well as prompt management with steroids are recommended.
Citation Format: Powell CA, Camidge DR, Gemma A, Kusumoto M, Baba T, Kuwano K, Bankier A, Kiura K, Tamura K, Modi S, Tsurutani J, Doi T, Iwata H, Krop IE, Zhang L, Jasmeet S, Saito K, Shahidi J, Yver A, Takahashi S. Characterization, monitoring and management of interstitial lung disease in patients with metastatic breast cancer: Analysis of data available from multiple studies of DS-8201a, a HER2-targeted antibody drug conjugate with a topoisomerase I inhibitor payload [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P6-17-06.
Collapse
Affiliation(s)
- CA Powell
- Icahn School of Medicine at Mount Sinai, New York, NY; University of Colorado Denver School of Medicine, Denver, CO; Nippon Medical School, Tokyo, Japan; National Cancer Center Hospital, Tokyo, Japan; Kanagawa Cardiovascular and Respiratory Center, Yokohama, Japan; Jikei University School of Medicine, Tokyo, Japan; Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA; Okayama University Hospital, Okayama, Japan; Memorial Sloan-Kettering Cancer Center, New York, NY; Kindai University Faculty of Medicine, Osaka, Japan; National Cancer Center Hospital East, Chiba, Japan; Aichi Cancer Center Hospital, Nagoya, Japan; Dana-Farber Cancer Institute, Boston, MA; Daiichi Sankyo, Inc., Basking Ridge, NJ; Daiichi Sankyo Co., Ltd., Tokyo, Japan; The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan
| | - DR Camidge
- Icahn School of Medicine at Mount Sinai, New York, NY; University of Colorado Denver School of Medicine, Denver, CO; Nippon Medical School, Tokyo, Japan; National Cancer Center Hospital, Tokyo, Japan; Kanagawa Cardiovascular and Respiratory Center, Yokohama, Japan; Jikei University School of Medicine, Tokyo, Japan; Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA; Okayama University Hospital, Okayama, Japan; Memorial Sloan-Kettering Cancer Center, New York, NY; Kindai University Faculty of Medicine, Osaka, Japan; National Cancer Center Hospital East, Chiba, Japan; Aichi Cancer Center Hospital, Nagoya, Japan; Dana-Farber Cancer Institute, Boston, MA; Daiichi Sankyo, Inc., Basking Ridge, NJ; Daiichi Sankyo Co., Ltd., Tokyo, Japan; The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan
| | - A Gemma
- Icahn School of Medicine at Mount Sinai, New York, NY; University of Colorado Denver School of Medicine, Denver, CO; Nippon Medical School, Tokyo, Japan; National Cancer Center Hospital, Tokyo, Japan; Kanagawa Cardiovascular and Respiratory Center, Yokohama, Japan; Jikei University School of Medicine, Tokyo, Japan; Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA; Okayama University Hospital, Okayama, Japan; Memorial Sloan-Kettering Cancer Center, New York, NY; Kindai University Faculty of Medicine, Osaka, Japan; National Cancer Center Hospital East, Chiba, Japan; Aichi Cancer Center Hospital, Nagoya, Japan; Dana-Farber Cancer Institute, Boston, MA; Daiichi Sankyo, Inc., Basking Ridge, NJ; Daiichi Sankyo Co., Ltd., Tokyo, Japan; The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan
| | - M Kusumoto
- Icahn School of Medicine at Mount Sinai, New York, NY; University of Colorado Denver School of Medicine, Denver, CO; Nippon Medical School, Tokyo, Japan; National Cancer Center Hospital, Tokyo, Japan; Kanagawa Cardiovascular and Respiratory Center, Yokohama, Japan; Jikei University School of Medicine, Tokyo, Japan; Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA; Okayama University Hospital, Okayama, Japan; Memorial Sloan-Kettering Cancer Center, New York, NY; Kindai University Faculty of Medicine, Osaka, Japan; National Cancer Center Hospital East, Chiba, Japan; Aichi Cancer Center Hospital, Nagoya, Japan; Dana-Farber Cancer Institute, Boston, MA; Daiichi Sankyo, Inc., Basking Ridge, NJ; Daiichi Sankyo Co., Ltd., Tokyo, Japan; The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan
| | - T Baba
- Icahn School of Medicine at Mount Sinai, New York, NY; University of Colorado Denver School of Medicine, Denver, CO; Nippon Medical School, Tokyo, Japan; National Cancer Center Hospital, Tokyo, Japan; Kanagawa Cardiovascular and Respiratory Center, Yokohama, Japan; Jikei University School of Medicine, Tokyo, Japan; Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA; Okayama University Hospital, Okayama, Japan; Memorial Sloan-Kettering Cancer Center, New York, NY; Kindai University Faculty of Medicine, Osaka, Japan; National Cancer Center Hospital East, Chiba, Japan; Aichi Cancer Center Hospital, Nagoya, Japan; Dana-Farber Cancer Institute, Boston, MA; Daiichi Sankyo, Inc., Basking Ridge, NJ; Daiichi Sankyo Co., Ltd., Tokyo, Japan; The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan
| | - K Kuwano
- Icahn School of Medicine at Mount Sinai, New York, NY; University of Colorado Denver School of Medicine, Denver, CO; Nippon Medical School, Tokyo, Japan; National Cancer Center Hospital, Tokyo, Japan; Kanagawa Cardiovascular and Respiratory Center, Yokohama, Japan; Jikei University School of Medicine, Tokyo, Japan; Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA; Okayama University Hospital, Okayama, Japan; Memorial Sloan-Kettering Cancer Center, New York, NY; Kindai University Faculty of Medicine, Osaka, Japan; National Cancer Center Hospital East, Chiba, Japan; Aichi Cancer Center Hospital, Nagoya, Japan; Dana-Farber Cancer Institute, Boston, MA; Daiichi Sankyo, Inc., Basking Ridge, NJ; Daiichi Sankyo Co., Ltd., Tokyo, Japan; The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan
| | - A Bankier
- Icahn School of Medicine at Mount Sinai, New York, NY; University of Colorado Denver School of Medicine, Denver, CO; Nippon Medical School, Tokyo, Japan; National Cancer Center Hospital, Tokyo, Japan; Kanagawa Cardiovascular and Respiratory Center, Yokohama, Japan; Jikei University School of Medicine, Tokyo, Japan; Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA; Okayama University Hospital, Okayama, Japan; Memorial Sloan-Kettering Cancer Center, New York, NY; Kindai University Faculty of Medicine, Osaka, Japan; National Cancer Center Hospital East, Chiba, Japan; Aichi Cancer Center Hospital, Nagoya, Japan; Dana-Farber Cancer Institute, Boston, MA; Daiichi Sankyo, Inc., Basking Ridge, NJ; Daiichi Sankyo Co., Ltd., Tokyo, Japan; The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan
| | - K Kiura
- Icahn School of Medicine at Mount Sinai, New York, NY; University of Colorado Denver School of Medicine, Denver, CO; Nippon Medical School, Tokyo, Japan; National Cancer Center Hospital, Tokyo, Japan; Kanagawa Cardiovascular and Respiratory Center, Yokohama, Japan; Jikei University School of Medicine, Tokyo, Japan; Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA; Okayama University Hospital, Okayama, Japan; Memorial Sloan-Kettering Cancer Center, New York, NY; Kindai University Faculty of Medicine, Osaka, Japan; National Cancer Center Hospital East, Chiba, Japan; Aichi Cancer Center Hospital, Nagoya, Japan; Dana-Farber Cancer Institute, Boston, MA; Daiichi Sankyo, Inc., Basking Ridge, NJ; Daiichi Sankyo Co., Ltd., Tokyo, Japan; The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan
| | - K Tamura
- Icahn School of Medicine at Mount Sinai, New York, NY; University of Colorado Denver School of Medicine, Denver, CO; Nippon Medical School, Tokyo, Japan; National Cancer Center Hospital, Tokyo, Japan; Kanagawa Cardiovascular and Respiratory Center, Yokohama, Japan; Jikei University School of Medicine, Tokyo, Japan; Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA; Okayama University Hospital, Okayama, Japan; Memorial Sloan-Kettering Cancer Center, New York, NY; Kindai University Faculty of Medicine, Osaka, Japan; National Cancer Center Hospital East, Chiba, Japan; Aichi Cancer Center Hospital, Nagoya, Japan; Dana-Farber Cancer Institute, Boston, MA; Daiichi Sankyo, Inc., Basking Ridge, NJ; Daiichi Sankyo Co., Ltd., Tokyo, Japan; The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan
| | - S Modi
- Icahn School of Medicine at Mount Sinai, New York, NY; University of Colorado Denver School of Medicine, Denver, CO; Nippon Medical School, Tokyo, Japan; National Cancer Center Hospital, Tokyo, Japan; Kanagawa Cardiovascular and Respiratory Center, Yokohama, Japan; Jikei University School of Medicine, Tokyo, Japan; Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA; Okayama University Hospital, Okayama, Japan; Memorial Sloan-Kettering Cancer Center, New York, NY; Kindai University Faculty of Medicine, Osaka, Japan; National Cancer Center Hospital East, Chiba, Japan; Aichi Cancer Center Hospital, Nagoya, Japan; Dana-Farber Cancer Institute, Boston, MA; Daiichi Sankyo, Inc., Basking Ridge, NJ; Daiichi Sankyo Co., Ltd., Tokyo, Japan; The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan
| | - J Tsurutani
- Icahn School of Medicine at Mount Sinai, New York, NY; University of Colorado Denver School of Medicine, Denver, CO; Nippon Medical School, Tokyo, Japan; National Cancer Center Hospital, Tokyo, Japan; Kanagawa Cardiovascular and Respiratory Center, Yokohama, Japan; Jikei University School of Medicine, Tokyo, Japan; Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA; Okayama University Hospital, Okayama, Japan; Memorial Sloan-Kettering Cancer Center, New York, NY; Kindai University Faculty of Medicine, Osaka, Japan; National Cancer Center Hospital East, Chiba, Japan; Aichi Cancer Center Hospital, Nagoya, Japan; Dana-Farber Cancer Institute, Boston, MA; Daiichi Sankyo, Inc., Basking Ridge, NJ; Daiichi Sankyo Co., Ltd., Tokyo, Japan; The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan
| | - T Doi
- Icahn School of Medicine at Mount Sinai, New York, NY; University of Colorado Denver School of Medicine, Denver, CO; Nippon Medical School, Tokyo, Japan; National Cancer Center Hospital, Tokyo, Japan; Kanagawa Cardiovascular and Respiratory Center, Yokohama, Japan; Jikei University School of Medicine, Tokyo, Japan; Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA; Okayama University Hospital, Okayama, Japan; Memorial Sloan-Kettering Cancer Center, New York, NY; Kindai University Faculty of Medicine, Osaka, Japan; National Cancer Center Hospital East, Chiba, Japan; Aichi Cancer Center Hospital, Nagoya, Japan; Dana-Farber Cancer Institute, Boston, MA; Daiichi Sankyo, Inc., Basking Ridge, NJ; Daiichi Sankyo Co., Ltd., Tokyo, Japan; The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan
| | - H Iwata
- Icahn School of Medicine at Mount Sinai, New York, NY; University of Colorado Denver School of Medicine, Denver, CO; Nippon Medical School, Tokyo, Japan; National Cancer Center Hospital, Tokyo, Japan; Kanagawa Cardiovascular and Respiratory Center, Yokohama, Japan; Jikei University School of Medicine, Tokyo, Japan; Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA; Okayama University Hospital, Okayama, Japan; Memorial Sloan-Kettering Cancer Center, New York, NY; Kindai University Faculty of Medicine, Osaka, Japan; National Cancer Center Hospital East, Chiba, Japan; Aichi Cancer Center Hospital, Nagoya, Japan; Dana-Farber Cancer Institute, Boston, MA; Daiichi Sankyo, Inc., Basking Ridge, NJ; Daiichi Sankyo Co., Ltd., Tokyo, Japan; The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan
| | - IE Krop
- Icahn School of Medicine at Mount Sinai, New York, NY; University of Colorado Denver School of Medicine, Denver, CO; Nippon Medical School, Tokyo, Japan; National Cancer Center Hospital, Tokyo, Japan; Kanagawa Cardiovascular and Respiratory Center, Yokohama, Japan; Jikei University School of Medicine, Tokyo, Japan; Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA; Okayama University Hospital, Okayama, Japan; Memorial Sloan-Kettering Cancer Center, New York, NY; Kindai University Faculty of Medicine, Osaka, Japan; National Cancer Center Hospital East, Chiba, Japan; Aichi Cancer Center Hospital, Nagoya, Japan; Dana-Farber Cancer Institute, Boston, MA; Daiichi Sankyo, Inc., Basking Ridge, NJ; Daiichi Sankyo Co., Ltd., Tokyo, Japan; The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan
| | - L Zhang
- Icahn School of Medicine at Mount Sinai, New York, NY; University of Colorado Denver School of Medicine, Denver, CO; Nippon Medical School, Tokyo, Japan; National Cancer Center Hospital, Tokyo, Japan; Kanagawa Cardiovascular and Respiratory Center, Yokohama, Japan; Jikei University School of Medicine, Tokyo, Japan; Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA; Okayama University Hospital, Okayama, Japan; Memorial Sloan-Kettering Cancer Center, New York, NY; Kindai University Faculty of Medicine, Osaka, Japan; National Cancer Center Hospital East, Chiba, Japan; Aichi Cancer Center Hospital, Nagoya, Japan; Dana-Farber Cancer Institute, Boston, MA; Daiichi Sankyo, Inc., Basking Ridge, NJ; Daiichi Sankyo Co., Ltd., Tokyo, Japan; The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan
| | - S Jasmeet
- Icahn School of Medicine at Mount Sinai, New York, NY; University of Colorado Denver School of Medicine, Denver, CO; Nippon Medical School, Tokyo, Japan; National Cancer Center Hospital, Tokyo, Japan; Kanagawa Cardiovascular and Respiratory Center, Yokohama, Japan; Jikei University School of Medicine, Tokyo, Japan; Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA; Okayama University Hospital, Okayama, Japan; Memorial Sloan-Kettering Cancer Center, New York, NY; Kindai University Faculty of Medicine, Osaka, Japan; National Cancer Center Hospital East, Chiba, Japan; Aichi Cancer Center Hospital, Nagoya, Japan; Dana-Farber Cancer Institute, Boston, MA; Daiichi Sankyo, Inc., Basking Ridge, NJ; Daiichi Sankyo Co., Ltd., Tokyo, Japan; The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan
| | - K Saito
- Icahn School of Medicine at Mount Sinai, New York, NY; University of Colorado Denver School of Medicine, Denver, CO; Nippon Medical School, Tokyo, Japan; National Cancer Center Hospital, Tokyo, Japan; Kanagawa Cardiovascular and Respiratory Center, Yokohama, Japan; Jikei University School of Medicine, Tokyo, Japan; Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA; Okayama University Hospital, Okayama, Japan; Memorial Sloan-Kettering Cancer Center, New York, NY; Kindai University Faculty of Medicine, Osaka, Japan; National Cancer Center Hospital East, Chiba, Japan; Aichi Cancer Center Hospital, Nagoya, Japan; Dana-Farber Cancer Institute, Boston, MA; Daiichi Sankyo, Inc., Basking Ridge, NJ; Daiichi Sankyo Co., Ltd., Tokyo, Japan; The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan
| | - J Shahidi
- Icahn School of Medicine at Mount Sinai, New York, NY; University of Colorado Denver School of Medicine, Denver, CO; Nippon Medical School, Tokyo, Japan; National Cancer Center Hospital, Tokyo, Japan; Kanagawa Cardiovascular and Respiratory Center, Yokohama, Japan; Jikei University School of Medicine, Tokyo, Japan; Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA; Okayama University Hospital, Okayama, Japan; Memorial Sloan-Kettering Cancer Center, New York, NY; Kindai University Faculty of Medicine, Osaka, Japan; National Cancer Center Hospital East, Chiba, Japan; Aichi Cancer Center Hospital, Nagoya, Japan; Dana-Farber Cancer Institute, Boston, MA; Daiichi Sankyo, Inc., Basking Ridge, NJ; Daiichi Sankyo Co., Ltd., Tokyo, Japan; The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan
| | - A Yver
- Icahn School of Medicine at Mount Sinai, New York, NY; University of Colorado Denver School of Medicine, Denver, CO; Nippon Medical School, Tokyo, Japan; National Cancer Center Hospital, Tokyo, Japan; Kanagawa Cardiovascular and Respiratory Center, Yokohama, Japan; Jikei University School of Medicine, Tokyo, Japan; Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA; Okayama University Hospital, Okayama, Japan; Memorial Sloan-Kettering Cancer Center, New York, NY; Kindai University Faculty of Medicine, Osaka, Japan; National Cancer Center Hospital East, Chiba, Japan; Aichi Cancer Center Hospital, Nagoya, Japan; Dana-Farber Cancer Institute, Boston, MA; Daiichi Sankyo, Inc., Basking Ridge, NJ; Daiichi Sankyo Co., Ltd., Tokyo, Japan; The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan
| | - S Takahashi
- Icahn School of Medicine at Mount Sinai, New York, NY; University of Colorado Denver School of Medicine, Denver, CO; Nippon Medical School, Tokyo, Japan; National Cancer Center Hospital, Tokyo, Japan; Kanagawa Cardiovascular and Respiratory Center, Yokohama, Japan; Jikei University School of Medicine, Tokyo, Japan; Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA; Okayama University Hospital, Okayama, Japan; Memorial Sloan-Kettering Cancer Center, New York, NY; Kindai University Faculty of Medicine, Osaka, Japan; National Cancer Center Hospital East, Chiba, Japan; Aichi Cancer Center Hospital, Nagoya, Japan; Dana-Farber Cancer Institute, Boston, MA; Daiichi Sankyo, Inc., Basking Ridge, NJ; Daiichi Sankyo Co., Ltd., Tokyo, Japan; The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan
| |
Collapse
|
69
|
Doi T, Kawarada O, Matsuyama TA, Ayabe S, Ishibashi-Ueda H, Noguchi T, Ogawa H, Yasuda S. Successful use of last-option infrapopliteal rotational atherectomy despite microembolisation: Peripheral rotational atherectomy and microembolisation. AsiaIntervention 2019; 5:53-56. [PMID: 34912973 PMCID: PMC8525721 DOI: 10.4244/aij-d-18-00057] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/01/2015] [Accepted: 12/20/2018] [Indexed: 06/14/2023]
Abstract
Calcified lesions pose a technical challenge even in contemporary endovascular intervention. A 71-year-old man who had been receiving haemodialysis required infrapopliteal revascularisation for the treatment of ischaemic infectious gangrene of the right toes. Baseline angiography suggested that the multiple stenotic lesions in the anterior tibial artery were amenable to endovascular therapy for the purpose of establishing one straight-line flow to the foot. However, even a 1.25×15 mm semi-compliant balloon catheter failed to cross and dilate the focal lesion because of the underlying severe calcification in the mid segment of the anterior tibial artery. We adjunctively used high-speed rotational atherectomy with the ROTABLATOR device (1.5 mm burr) to ablate the focal calcified lesion while paying attention to minimise the ablation length and the ablation time. Subsequent balloon angioplasty with a 2.0×40 mm balloon catheter was successful. The skin perfusion pressure in the right foot increased from 32 to 48 mmHg, suggesting a high probability of wound healing. Pathological examination of the right toe amputated on schedule found non-clinically relevant microembolisation involving a couple of cholesterol crystals (20-30 µm) located in the arterioles and capillaries of the necrotic tissue. As an adjunctive device, the ROTABLATOR could provide a last resort for limb salvage, albeit that microembolisation can occur.
Collapse
Affiliation(s)
- Takahito Doi
- Department of Cardiovascular Medicine, National Cerebral and Cardiovascular Center, Osaka, Japan
| | - Osami Kawarada
- Department of Cardiovascular Medicine, National Cerebral and Cardiovascular Center, Osaka, Japan
- Department of Cardiovascular Medicine, Ikuwakai Memorial Hospital, Osaka, Japan
| | - Taka-Aki Matsuyama
- Department of Pathology, National Cerebral and Cardiovascular Center, Osaka, Japan
| | - Shinobu Ayabe
- Department of Plastic Surgery, Yao Tokushukai General Hospital, Osaka, Japan
| | | | - Teruo Noguchi
- Department of Cardiovascular Medicine, National Cerebral and Cardiovascular Center, Osaka, Japan
| | - Hisao Ogawa
- Department of Cardiovascular Medicine, National Cerebral and Cardiovascular Center, Osaka, Japan
| | - Satoshi Yasuda
- Department of Cardiovascular Medicine, National Cerebral and Cardiovascular Center, Osaka, Japan
| |
Collapse
|
70
|
Ishii H, Makizako H, Doi T, Tsutsumimoto K, Shimada H. Associations of Skeletal Muscle Mass, Lower-Extremity Functioning, and Cognitive Impairment in Community-Dwelling Older People in Japan. J Nutr Health Aging 2019; 23:35-41. [PMID: 30569066 DOI: 10.1007/s12603-018-1110-9] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
Abstract
OBJECTIVE We examined whether skeletal muscle mass and lower extremity functioning are closely associated with multiple cognitive domains, including global cognition, memory, attention, executive functioning, and processing speed, in community-dwelling older Japanese adults. DESIGN A cross-sectional, population-based community study. SETTING This study was conducted among community-living older people enrolled in the Obu Study of Health Promotion for the Elderly. PARTICIPANTS Participants comprised 5,104 adults (≥ 65 years, mean age: 71 years). MEASUREMENTS Data from 4273 participants were analyzed. Appendicular skeletal muscle mass was estimated from bioelectrical impedance analysis and expressed as appendicular skeletal muscle mass index (ASMI). Lower-extremity functioning was assessed by the Five-Times-Sit-to-Stand test (FTSS) and Timed Up and Go test (TUG). Cognitive functions were assessed by the Mini Mental State Examination, word list memory, Trail Making Test parts A and B, and Symbol Digit Substitution Task. Logistic regression analysis were performed to calculate odds ratios (ORs) of cognitive impairment in various domains among skeletal muscle mass, lower-extremity functioning levels adjusted for important demographic variables, and comorbidities. RESULTS Participants with lower ASMI and slower FTSS and TUG groups had lower cognitive functioning scores than did participants with higher ASMI and faster FTSS and TUG. The slowest quartiles (Q4) of FTSS and TUG were significantly associated with impaired global functioning (MMSE score < 24) compared to the fastest quartile (Q1) after multivariate adjustment (FTSS, OR = 1.46, 95% confidence interval (CI) = 1.12-1.90; TUG, OR = 1.65, 95% CI = 1.25-2.17). In other dimensions of cognitive functioning, FTSS and TUG were significantly associated with all cognitive impairment in the full adjustment model. CONCLUSION Lower-extremity functioning, rather than skeletal muscle mass, is closely related to multiple cognitive domains. This study suggests that maintaining lower-extremity functioning, rather than skeletal muscle mass, may be required for detecting and preventing cognitive impairment.
Collapse
Affiliation(s)
- H Ishii
- Hideaki Ishii, Section for Health Promotion, Department of Preventive Gerontology, Center for Gerontology and Social Science, National Center for Geriatrics and Gerontology, 7-430, Morioka-cho, Obu City, Aichi Prefecture 474-8511, Japan, Tel: +81-562-44-5651, Fax: +81-562-46-8294, e-mail:
| | | | | | | | | |
Collapse
|
71
|
Kimura F, Horii S, Arimoto I, Notsu D, Doi T, Wada M, Kimura T. X-ray diffraction study on the orientation dynamics of biaxial microcrystals under static and rotating magnetic fields. CrystEngComm 2019. [DOI: 10.1039/c9ce00599d] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
The orientation of microcrystals of DyBa2Cu3Oy (y ~ 7) under static and rotating magnetic fields was studied.
Collapse
Affiliation(s)
- F. Kimura
- Graduate School of Energy Science
- Kyoto University
- Kyoto 606-8501
- Japan
- Nagamori Institute of Actuators
| | - S. Horii
- Graduate School of Energy Science
- Kyoto University
- Kyoto 606-8501
- Japan
- Nagamori Institute of Actuators
| | - I. Arimoto
- Graduate School of Energy Science
- Kyoto University
- Kyoto 606-8501
- Japan
| | - D. Notsu
- Graduate School of Energy Science
- Kyoto University
- Kyoto 606-8501
- Japan
| | - T. Doi
- Graduate School of Energy Science
- Kyoto University
- Kyoto 606-8501
- Japan
| | - M. Wada
- Division of Forestry and Biomaterials
- Kyoto University
- Kyoto 606-8502
- Japan
- Department of Plant & Environmental New Resources
| | - T. Kimura
- Division of Forestry and Biomaterials
- Kyoto University
- Kyoto 606-8502
- Japan
- Fukui University of Technology
| |
Collapse
|
72
|
Shitara K, Tabernero J, Dvorkin M, Mansoor W, Arkenau HT, Prokharau A, Alsina M, Ghidini M, Faustino C, Gorbunova V, Zhavrid E, Nishikawa K, Hosokawa A, Ganea D, Yalçın Ş, Fujitani K, Beretta G, Winkler R, Doi T, Ilson D. Overall survival results from a phase III trial of trifluridine/tipiracil (FTD/TPI) vs placebo in patients (Pts) with metastatic gastric cancer refractory to standard therapies (TAGS). Ann Oncol 2018. [DOI: 10.1093/annonc/mdy432.027] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
73
|
Bang YJ, Doi T, Kondo S, Chung H, Muro K, Dussault I, Helwig C, Osada M, Kang YK. Updated results from a phase I trial of M7824 (MSB0011359C), a bifunctional fusion protein targeting PD-L1 and TGF-β, in patients with pretreated recurrent or refractory gastric cancer. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy282.045] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
74
|
Arkenau HT, Tabernero J, Shitara K, Dvorkin M, Mansoor W, Prokharau A, Alsina M, Ghidini M, Faustino C, Gorbunova V, Zhavrid E, Nishikawa K, Hosokawa A, Ganea D, Yalçın Ş, Beretta G, Winkler R, Makris L, Doi T, Ilson D. TAGS: A phase III, randomised, double-blind study of trifluridine/tipiracil (TAS-102) versus placebo in patients with refractory metastatic gastric cancer. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy424.027] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
75
|
Kato K, Shah M, Enzinger P, Bennouna J, Shen L, Adenis A, Sun JM, Cho B, Ozguroglu M, Kojima T, Kostorov V, Hierro C, Zhu Y, Shah S, Bhagia P, Doi T. Phase III KEYNOTE-590 study of chemotherapy + pembrolizumab versus chemotherapy + placebo as first-line therapy for patients (Pts) with advanced esophageal or esophagogastric junction (E/EGJ) cancer. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy282.168] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
76
|
Doi T, Iwasa S, Muro K, Satoh T, Hironaka S, Esaki T, Nishina T, Hara H, Machida N, Komatsu Y, Shimada Y, Otsu S, Shimizu S, Chand V, Watanabe M. Avelumab (anti–PD-L1) in Japanese patients with advanced gastric or gastroesophageal junction cancer (GC/GEJC): Updated results from the phase Ib JAVELIN solid tumour JPN trial. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy282.043] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
77
|
Lin CC, Doi T, Muro K, Hou MM, Esaki T, Hara H, Chung HC, Osada M, Helwig C, Kondo S. Phase I study results from an esophageal squamous cell carcinoma (ESCC) cohort treated with M7824 (MSB0011359C), a bifunctional fusion protein targeting transforming growth factor β (TGF-β) and PD-L1. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy282.026] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
78
|
Yoshino T, Iwata H, Tamura K, Takahashi S, Redfern C, Modi S, Doi T, Kawakami H, Taniguchi H, Takashima A, Yamaguchi K, Fisher J, Li B, Saito K, Fujisaki Y, Sugihara M, Tsurutani J. Updated results of phase I study of trastuzumab deruxtecan (DS-8201a) in HER2-expressing advanced colorectal cancer. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy281.109] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
79
|
Hamid O, Hu-Lieskovan S, Ros W, Diab A, El-Khoueiry A, Thompson J, Eskens F, Spano JP, Angevin E, Rizvi N, Wasser J, Ott P, Chiappori A, Joh T, Krupka H, Potluri S, Wang X, Ganguli B, Chou J, Doi T. Pharmacodynamic (PD) changes in tumors and peripheral blood T cell receptor (TCR) repertoire in a phase I study combining OX40 (PF-04518600) and 4-1BB (utomilumab) agonistic monoclonal antibodies (mAbs). Ann Oncol 2018. [DOI: 10.1093/annonc/mdy288.057] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
80
|
Tsuda K, Kataoka Y, Nishikawa R, Doi T, Nakashima T, Kawakami S, Fujino M, Nakao K, Nishihira K, Tahara Y, Asaumi Y, Noguchi T, Yasuda S. P906Diminished response to statin therapy predicts future occurrence of heart failure in patients with acute myocardial infarction. Eur Heart J 2018. [DOI: 10.1093/eurheartj/ehy564.p906] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Affiliation(s)
- K Tsuda
- National Cerebral and Cardiovascular Center Hospital, Department of Cardiovascular Medicine, Suita, Osaka, Japan
| | - Y Kataoka
- National Cerebral and Cardiovascular Center Hospital, Department of Cardiovascular Medicine, Suita, Osaka, Japan
| | - R Nishikawa
- National Cerebral and Cardiovascular Center Hospital, Department of Cardiovascular Medicine, Suita, Osaka, Japan
| | - T Doi
- National Cerebral and Cardiovascular Center Hospital, Department of Cardiovascular Medicine, Suita, Osaka, Japan
| | - T Nakashima
- National Cerebral and Cardiovascular Center Hospital, Department of Cardiovascular Medicine, Suita, Osaka, Japan
| | - S Kawakami
- National Cerebral and Cardiovascular Center Hospital, Department of Cardiovascular Medicine, Suita, Osaka, Japan
| | - M Fujino
- National Cerebral and Cardiovascular Center Hospital, Department of Cardiovascular Medicine, Suita, Osaka, Japan
| | - K Nakao
- National Cerebral and Cardiovascular Center Hospital, Department of Cardiovascular Medicine, Suita, Osaka, Japan
| | - K Nishihira
- National Cerebral and Cardiovascular Center Hospital, Department of Cardiovascular Medicine, Suita, Osaka, Japan
| | - Y Tahara
- National Cerebral and Cardiovascular Center Hospital, Department of Cardiovascular Medicine, Suita, Osaka, Japan
| | - Y Asaumi
- National Cerebral and Cardiovascular Center Hospital, Department of Cardiovascular Medicine, Suita, Osaka, Japan
| | - T Noguchi
- National Cerebral and Cardiovascular Center Hospital, Department of Cardiovascular Medicine, Suita, Osaka, Japan
| | - S Yasuda
- National Cerebral and Cardiovascular Center Hospital, Department of Cardiovascular Medicine, Suita, Osaka, Japan
| |
Collapse
|
81
|
Koyama M, Furuhashi M, Nagano N, Fujita Y, Moniwa N, Yano T, Doi T, Takahashi T, Ohnishi H, Miura T. P3508Cardiac iodine-123 metaiodobenzylguanidine imaging predicts frequent hypotension during hemodialysis in patients with end-stage renal disease. Eur Heart J 2018. [DOI: 10.1093/eurheartj/ehy563.p3508] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Affiliation(s)
- M Koyama
- Sapporo Medical University, Department of Cardiovascular, Renal and Metabolic Medicine, Sapporo, Japan
| | - M Furuhashi
- Sapporo Medical University, Department of Cardiovascular, Renal and Metabolic Medicine, Sapporo, Japan
| | - N Nagano
- Sapporo Medical University, Department of Cardiovascular, Renal and Metabolic Medicine, Sapporo, Japan
| | - Y Fujita
- Sapporo Medical University, Department of Cardiovascular, Renal and Metabolic Medicine, Sapporo, Japan
| | - N Moniwa
- Sapporo Medical University, Department of Cardiovascular, Renal and Metabolic Medicine, Sapporo, Japan
| | - T Yano
- Sapporo Medical University, Department of Cardiovascular, Renal and Metabolic Medicine, Sapporo, Japan
| | - T Doi
- Teine Keijinkai Hospital, Division of Cardiology, Cardiovascular center, Sapporo, Japan
| | - T Takahashi
- Obihiro Kosei Hospital, Department of Cardiovascular Internal Medicine, Obihiro, Japan
| | - H Ohnishi
- Sapporo Medical University, Department of Public Health, Sapporo, Japan
| | - T Miura
- Sapporo Medical University, Department of Cardiovascular, Renal and Metabolic Medicine, Sapporo, Japan
| |
Collapse
|
82
|
Kato K, Shah M, Enzinger P, Bennouna J, Shen L, Adenis A, Sun J, Cho B, Ozguroglu M, Kojima T, Kostorov V, Hierro C, Zhu Y, Shah S, Bhagia P, Doi T. A phase 3 study of chemotherapy + pembrolizumab versus chemotherapy + placebo as first-line therapy for patients with advanced esophageal or esophagogastric junction (E/EGJ) cancer: KEYNOTE-590 - Trial in progress. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy151.051] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
83
|
Tabernero J, Shitara K, Dvorkin M, Mansoor W, Arkenau HT, Prokharau A, Alsina M, Ghidini M, Faustino C, Gorbunova V, Zhavrid E, Nishikawa K, Hosokawa A, Ganea D, Yalçın Ş, Fujitani K, Beretta G, Winkler R, Makris L, Doi T, Ilson D. Overall survival results from a phase III trial of trifluridine/tipiracil versus placebo in patients with metastatic gastric cancer refractory to standard therapies (TAGS). Ann Oncol 2018. [DOI: 10.1093/annonc/mdy208.001] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/12/2023] Open
|
84
|
Doi T, Kawarada O, Yagyu T, Noguchi T, Yasuda S. Iliac artery stent fracture associated with hip joint flexion. Cardiovasc Interv Ther 2018; 34:180-181. [PMID: 29730852 DOI: 10.1007/s12928-018-0525-x] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/19/2018] [Accepted: 04/30/2018] [Indexed: 11/29/2022]
Affiliation(s)
- Takahito Doi
- Department of Cardiovascular Medicine, National Cerebral and Cardiovascular Center, 5-7-1 Fujishiro-dai, Suita, Osaka, 565-8565, Japan.,Department of Advanced Cardiovascular Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan
| | - Osami Kawarada
- Department of Cardiovascular Medicine, National Cerebral and Cardiovascular Center, 5-7-1 Fujishiro-dai, Suita, Osaka, 565-8565, Japan.
| | - Takeshi Yagyu
- Department of Cardiovascular Medicine, National Cerebral and Cardiovascular Center, 5-7-1 Fujishiro-dai, Suita, Osaka, 565-8565, Japan
| | - Teruo Noguchi
- Department of Cardiovascular Medicine, National Cerebral and Cardiovascular Center, 5-7-1 Fujishiro-dai, Suita, Osaka, 565-8565, Japan
| | - Satoshi Yasuda
- Department of Cardiovascular Medicine, National Cerebral and Cardiovascular Center, 5-7-1 Fujishiro-dai, Suita, Osaka, 565-8565, Japan.,Department of Advanced Cardiovascular Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan
| |
Collapse
|
85
|
Nakakubo S, Makizako H, Doi T, Tsutsumimoto K, Hotta R, Lee S, Lee S, Bae S, Makino K, Suzuki T, Shimada H. Long and Short Sleep Duration and Physical Frailty in Community-Dwelling Older Adults. J Nutr Health Aging 2018; 22:1066-1071. [PMID: 30379304 DOI: 10.1007/s12603-018-1116-3] [Citation(s) in RCA: 24] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/18/2022]
Abstract
OBJECTIVE The objective of this study was to investigate whether older adults who have a particularly long sleep duration are likely to exhibit physical frailty, similar to those with a particularly short sleep duration. DESIGN Cross-sectional study. SETTING The National Center for Geriatrics and Gerontology - Study of Geriatric Syndromes. PARTICIPANTS A total of 9,824 older adults (mean age: 73.6 ± 5.5 years, 4,812 men and 5,012 women) met the entry criteria for this study. MEASUREMENTS We divided the participants into three groups according to self-reported sleep duration (Short: ≤6 h, Mid: 6.1-8.9 h (control), Long: ≥ 9 h). Physical frailty was characterized based on the criteria from the Cardiovascular Health Study. Multinomial logistic regression analysis was performed to evaluate the effect of sleep duration on physical frailty by sex. RESULTS Among all participants, the prevalence of physical frailty was higher in the Short (10.5%) and Long (17.9%) groups than in the Mid (7.4%) group (p < 0.001). Multinomial logistic regression analysis showed that both Short and Long groups had a significantly higher odds ratio (OR) for physical frailty than the Mid group [Short: OR 1.53, 95% confidence interval (CI) 1.26-1.87; Long: OR 2.39, 95% CI 1.90-3.00], even after adjusting for age, educational level, number of medications, body mass index, Mini Mental State Examination score, current smoking and alcohol habits, self-perceived health, and medical history. CONCLUSION Both long and short sleep durations were associated with physical frailty. Further studies are required to confirm the effect of sleep duration on the incidence or worsening of physical frailty in older adults.
Collapse
Affiliation(s)
- S Nakakubo
- Sho Nakakubo, Section of Health Promotion, Department of Preventive Gerontology, Center for Gerontology and Social Science, National Center for Geriatrics and Gerontology, Obu, Japan, 7-430, Morioka, Obu, Aichi 474-8511, Japan, Tel: +81-562-44-5651, Fax: +81-562-46-8294 , E-mail:
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
86
|
Tsutsumimoto K, Doi T, Makizako H, Hotta R, Nakakubo S, Makino K, Suzuki T, Shimada H. Cognitive Frailty is Associated with Fall-Related Fracture among Older People. J Nutr Health Aging 2018; 22:1216-1220. [PMID: 30498829 DOI: 10.1007/s12603-018-1131-4] [Citation(s) in RCA: 22] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Abstract
OBJECTIVE Cognitive frailty refers to cognitive impairment and physical frailty. Both cognitive impairment and physical frailty include risks of falling. The purpose of the study is to examine cognitive frailty and falling with/without a fracture. DESIGN Cross-sectional observation study. SETTING General communities in Japan. PARTICIPANTS Data of 10,202 older adults aged ≥ 65 years were collected. MEASUREMENTS Physical frailty was characterized as slow walking speed and/or muscle weakness. Assessment of cognitive function included word lists memory, attention, executive function, and processing speed. Cognitive impairment refers to one or more cognitive decline indicated by at least 1.5 standard deviations below the threshold after adjusting for age and education. We operationally defined cognitive frailty as having both cognitive impairment and physical frailty. Participants were interviewed about their falling, history of fall-related fractures, and several potentially confounding factors such as demographic characteristics. RESULTS Multinomial logistic regression analysis revealed that functional decline in all groups, as compared to the robust group, was significantly associated with falling without fractures, after adjusting for the covariates; cognitive impairment group (P = .017), physical frailty group (P = .002), and cognitive frailty group (P < .001). Only the cognitive frailty group had a significant association with fall-related fracture after adjusting for the covariates (OR 1.92, 95% CI: 1.20-3.08, P = .007). CONCLUSION Cognitive frailty is associated with not only falling but also fall-related fractures. Cognitive frailty may have a greater risk for fall-related fractures than cognitive impairment or physical frailty alone. Future research should examine causal the relationship between fall-related fractures and cognitive frailty.
Collapse
Affiliation(s)
- K Tsutsumimoto
- Kota Tsutsumimoto, Section for Health Promotion, Department of Preventive Gerontology, Center for Gerontology and Social Science, National Center for Geriatrics and Gerontology, 7-430, Morioka-cho, Obu City, Aichi Prefecture 474-8511, Japan, Tel: +81-562-44-5651, Fax: +81-562-46-8294, E-mail:
| | | | | | | | | | | | | | | |
Collapse
|
87
|
Doi T, Makizako H, Tsutsumimoto K, Hotta R, Nakakubo S, Makino K, Suzuki T, Shimada H. Association between Insulin-Like Growth Factor-1 and Frailty among Older Adults. J Nutr Health Aging 2018; 22:68-72. [PMID: 29300424 DOI: 10.1007/s12603-017-0916-1] [Citation(s) in RCA: 20] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
Abstract
OBJECTIVES Frailty is a course experienced in advanced aging. Identification of a biological factor associated with frailty is required. Although serum insulin-like growth factor-1 (IGF-1) is a potential factor related with frailty, consensus has not been reached regarding this relationship. This study aimed to investigate the association between IGF-1 and frailty in older adults. DESIGN Cross-sectional study. SETTING Cohort study that was part of the "National Center for Geriatrics and Gerontology - Study of Geriatric Syndromes." PARTICIPANTS The study participants were 4133 older adults (mean age, 71.8 ± 5.4 years). MEASUREMENTS We assessed serum IGF-1 levels and frailty status and collected demographic variables, including cognitive function, as covariates. RESULTS Frailty and pre-frailty were present in 274 subjects (7%) and 1930 subjects (47%), respectively. Subjects were divided into four groups based on quartiles of IGF-1 levels. Multinomial logistic analysis showed that the lowest group had significant odds of pre-frailty (crude model: odds ratio [OR] 1.58, 95% confidence interval [CI] 1.30-1.90, p < .001; adjusted model: OR 1.38, 95% CI 1.13-1.68, p = .002) and frailty (crude model: OR 3.42, 95% CI 2.38-4.92, p < .001; adjusted model: OR 1.54, 95% CI 1.02-2.32, p = .039), compared with the highest group. CONCLUSION Lower serum IGF-1 levels were independently related with frailty in older adults.
Collapse
Affiliation(s)
- T Doi
- Takehiko Doi, Department of Preventive Gerontology, Center for Gerontology and Social Science, National Center for Geriatrics and Gerontology, 7-430, Morioka, Obu, Aichi 474-8511, Japan, Tel.: +81-562-44-5651, Fax: +81-562-46-8294, E-mail:
| | | | | | | | | | | | | | | |
Collapse
|
88
|
Doi T, Kataoka Y, Noguchi T, Shibata T, Nakashima T, Kawakami S, Nakao K, Fujino M, Nagai T, Kanaya T, Tahara Y, Asaumi Y, Tsuda E, Nakai M, Nishimura K, Anzai T, Kusano K, Shimokawa H, Goto Y, Yasuda S. Coronary Artery Ectasia Predicts Future Cardiac Events in Patients With Acute Myocardial Infarction. Arterioscler Thromb Vasc Biol 2017; 37:2350-2355. [DOI: 10.1161/atvbaha.117.309683] [Citation(s) in RCA: 67] [Impact Index Per Article: 9.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/17/2017] [Accepted: 09/25/2017] [Indexed: 12/23/2022]
Abstract
Objective—
Coronary artery ectasia (CAE) is an infrequently observed vascular phenotype characterized by abnormal vessel dilatation and disturbed coronary flow, which potentially promote thrombogenicity and inflammatory reactions. However, whether or not CAE influences cardiovascular outcomes remains unknown.
Approach and Results—
We investigated major adverse cardiac events (MACE; defined as cardiac death and nonfatal myocardial infarction [MI]) in 1698 patients with acute MI. The occurrence of MACE was compared in patients with and without CAE. CAE was identified in 3.0% of study subjects. During the 49-month observation period, CAE was associated with 3.25-, 2.71-, and 4.92-fold greater likelihoods of experiencing MACE (95% confidence interval [CI], 1.88–5.66;
P
<0.001), cardiac death (95% CI, 1.37–5.37;
P
=0.004), and nonfatal MI (95% CI, 2.20–11.0;
P
<0.001), respectively. These cardiac risks of CAE were consistently observed in a multivariate Cox proportional hazards model (MACE: hazard ratio, 4.94; 95% CI, 2.36–10.4;
P
<0.001) and in a propensity score–matched cohort (MACE: hazard ratio, 8.98; 95% CI, 1.14–71.0;
P
=0.03). Despite having a higher risk of CAE-related cardiac events, patients with CAE receiving anticoagulation therapy who achieved an optimal percent time in target therapeutic range, defined as ≥60%, did not experience the occurrence of MACE (
P
=0.03 versus patients with percent time in target therapeutic range <60% or without anticoagulation therapy).
Conclusions—
The presence of CAE predicted future cardiac events in patients with acute MI. Our findings suggest that acute MI patients with CAE are a high-risk subset who might benefit from a pharmacological approach to controlling the coagulation cascade.
Collapse
Affiliation(s)
- Takahito Doi
- From the Department of Cardiovascular Medicine (T.D., Y.K., T. Noguchi, T. Nakashima, S.K., K. Nakao, M.F., T. Nagai, T.K., Y.T., Y.A., T.A., K.K., Y.G., S.Y.), Department of Pediatric Cardiology (E.T.), and Department of Statistics and Data Analysis, Center for Cerebral and Cardiovascular Disease Information (M.N., K.N.), National Cerebral and Cardiovascular Center, Suita, Japan; Department of Advanced Cardiovascular Medicine (T.D., S.Y.) and Department of Cardiovascular Medicine (H.S.), Tohoku
| | - Yu Kataoka
- From the Department of Cardiovascular Medicine (T.D., Y.K., T. Noguchi, T. Nakashima, S.K., K. Nakao, M.F., T. Nagai, T.K., Y.T., Y.A., T.A., K.K., Y.G., S.Y.), Department of Pediatric Cardiology (E.T.), and Department of Statistics and Data Analysis, Center for Cerebral and Cardiovascular Disease Information (M.N., K.N.), National Cerebral and Cardiovascular Center, Suita, Japan; Department of Advanced Cardiovascular Medicine (T.D., S.Y.) and Department of Cardiovascular Medicine (H.S.), Tohoku
| | - Teruo Noguchi
- From the Department of Cardiovascular Medicine (T.D., Y.K., T. Noguchi, T. Nakashima, S.K., K. Nakao, M.F., T. Nagai, T.K., Y.T., Y.A., T.A., K.K., Y.G., S.Y.), Department of Pediatric Cardiology (E.T.), and Department of Statistics and Data Analysis, Center for Cerebral and Cardiovascular Disease Information (M.N., K.N.), National Cerebral and Cardiovascular Center, Suita, Japan; Department of Advanced Cardiovascular Medicine (T.D., S.Y.) and Department of Cardiovascular Medicine (H.S.), Tohoku
| | - Tatsuhiro Shibata
- From the Department of Cardiovascular Medicine (T.D., Y.K., T. Noguchi, T. Nakashima, S.K., K. Nakao, M.F., T. Nagai, T.K., Y.T., Y.A., T.A., K.K., Y.G., S.Y.), Department of Pediatric Cardiology (E.T.), and Department of Statistics and Data Analysis, Center for Cerebral and Cardiovascular Disease Information (M.N., K.N.), National Cerebral and Cardiovascular Center, Suita, Japan; Department of Advanced Cardiovascular Medicine (T.D., S.Y.) and Department of Cardiovascular Medicine (H.S.), Tohoku
| | - Takahiro Nakashima
- From the Department of Cardiovascular Medicine (T.D., Y.K., T. Noguchi, T. Nakashima, S.K., K. Nakao, M.F., T. Nagai, T.K., Y.T., Y.A., T.A., K.K., Y.G., S.Y.), Department of Pediatric Cardiology (E.T.), and Department of Statistics and Data Analysis, Center for Cerebral and Cardiovascular Disease Information (M.N., K.N.), National Cerebral and Cardiovascular Center, Suita, Japan; Department of Advanced Cardiovascular Medicine (T.D., S.Y.) and Department of Cardiovascular Medicine (H.S.), Tohoku
| | - Shoji Kawakami
- From the Department of Cardiovascular Medicine (T.D., Y.K., T. Noguchi, T. Nakashima, S.K., K. Nakao, M.F., T. Nagai, T.K., Y.T., Y.A., T.A., K.K., Y.G., S.Y.), Department of Pediatric Cardiology (E.T.), and Department of Statistics and Data Analysis, Center for Cerebral and Cardiovascular Disease Information (M.N., K.N.), National Cerebral and Cardiovascular Center, Suita, Japan; Department of Advanced Cardiovascular Medicine (T.D., S.Y.) and Department of Cardiovascular Medicine (H.S.), Tohoku
| | - Kazuhiro Nakao
- From the Department of Cardiovascular Medicine (T.D., Y.K., T. Noguchi, T. Nakashima, S.K., K. Nakao, M.F., T. Nagai, T.K., Y.T., Y.A., T.A., K.K., Y.G., S.Y.), Department of Pediatric Cardiology (E.T.), and Department of Statistics and Data Analysis, Center for Cerebral and Cardiovascular Disease Information (M.N., K.N.), National Cerebral and Cardiovascular Center, Suita, Japan; Department of Advanced Cardiovascular Medicine (T.D., S.Y.) and Department of Cardiovascular Medicine (H.S.), Tohoku
| | - Masashi Fujino
- From the Department of Cardiovascular Medicine (T.D., Y.K., T. Noguchi, T. Nakashima, S.K., K. Nakao, M.F., T. Nagai, T.K., Y.T., Y.A., T.A., K.K., Y.G., S.Y.), Department of Pediatric Cardiology (E.T.), and Department of Statistics and Data Analysis, Center for Cerebral and Cardiovascular Disease Information (M.N., K.N.), National Cerebral and Cardiovascular Center, Suita, Japan; Department of Advanced Cardiovascular Medicine (T.D., S.Y.) and Department of Cardiovascular Medicine (H.S.), Tohoku
| | - Toshiyuki Nagai
- From the Department of Cardiovascular Medicine (T.D., Y.K., T. Noguchi, T. Nakashima, S.K., K. Nakao, M.F., T. Nagai, T.K., Y.T., Y.A., T.A., K.K., Y.G., S.Y.), Department of Pediatric Cardiology (E.T.), and Department of Statistics and Data Analysis, Center for Cerebral and Cardiovascular Disease Information (M.N., K.N.), National Cerebral and Cardiovascular Center, Suita, Japan; Department of Advanced Cardiovascular Medicine (T.D., S.Y.) and Department of Cardiovascular Medicine (H.S.), Tohoku
| | - Tomoaki Kanaya
- From the Department of Cardiovascular Medicine (T.D., Y.K., T. Noguchi, T. Nakashima, S.K., K. Nakao, M.F., T. Nagai, T.K., Y.T., Y.A., T.A., K.K., Y.G., S.Y.), Department of Pediatric Cardiology (E.T.), and Department of Statistics and Data Analysis, Center for Cerebral and Cardiovascular Disease Information (M.N., K.N.), National Cerebral and Cardiovascular Center, Suita, Japan; Department of Advanced Cardiovascular Medicine (T.D., S.Y.) and Department of Cardiovascular Medicine (H.S.), Tohoku
| | - Yoshio Tahara
- From the Department of Cardiovascular Medicine (T.D., Y.K., T. Noguchi, T. Nakashima, S.K., K. Nakao, M.F., T. Nagai, T.K., Y.T., Y.A., T.A., K.K., Y.G., S.Y.), Department of Pediatric Cardiology (E.T.), and Department of Statistics and Data Analysis, Center for Cerebral and Cardiovascular Disease Information (M.N., K.N.), National Cerebral and Cardiovascular Center, Suita, Japan; Department of Advanced Cardiovascular Medicine (T.D., S.Y.) and Department of Cardiovascular Medicine (H.S.), Tohoku
| | - Yasuhide Asaumi
- From the Department of Cardiovascular Medicine (T.D., Y.K., T. Noguchi, T. Nakashima, S.K., K. Nakao, M.F., T. Nagai, T.K., Y.T., Y.A., T.A., K.K., Y.G., S.Y.), Department of Pediatric Cardiology (E.T.), and Department of Statistics and Data Analysis, Center for Cerebral and Cardiovascular Disease Information (M.N., K.N.), National Cerebral and Cardiovascular Center, Suita, Japan; Department of Advanced Cardiovascular Medicine (T.D., S.Y.) and Department of Cardiovascular Medicine (H.S.), Tohoku
| | - Etsuko Tsuda
- From the Department of Cardiovascular Medicine (T.D., Y.K., T. Noguchi, T. Nakashima, S.K., K. Nakao, M.F., T. Nagai, T.K., Y.T., Y.A., T.A., K.K., Y.G., S.Y.), Department of Pediatric Cardiology (E.T.), and Department of Statistics and Data Analysis, Center for Cerebral and Cardiovascular Disease Information (M.N., K.N.), National Cerebral and Cardiovascular Center, Suita, Japan; Department of Advanced Cardiovascular Medicine (T.D., S.Y.) and Department of Cardiovascular Medicine (H.S.), Tohoku
| | - Michikazu Nakai
- From the Department of Cardiovascular Medicine (T.D., Y.K., T. Noguchi, T. Nakashima, S.K., K. Nakao, M.F., T. Nagai, T.K., Y.T., Y.A., T.A., K.K., Y.G., S.Y.), Department of Pediatric Cardiology (E.T.), and Department of Statistics and Data Analysis, Center for Cerebral and Cardiovascular Disease Information (M.N., K.N.), National Cerebral and Cardiovascular Center, Suita, Japan; Department of Advanced Cardiovascular Medicine (T.D., S.Y.) and Department of Cardiovascular Medicine (H.S.), Tohoku
| | - Kunihiro Nishimura
- From the Department of Cardiovascular Medicine (T.D., Y.K., T. Noguchi, T. Nakashima, S.K., K. Nakao, M.F., T. Nagai, T.K., Y.T., Y.A., T.A., K.K., Y.G., S.Y.), Department of Pediatric Cardiology (E.T.), and Department of Statistics and Data Analysis, Center for Cerebral and Cardiovascular Disease Information (M.N., K.N.), National Cerebral and Cardiovascular Center, Suita, Japan; Department of Advanced Cardiovascular Medicine (T.D., S.Y.) and Department of Cardiovascular Medicine (H.S.), Tohoku
| | - Toshihisa Anzai
- From the Department of Cardiovascular Medicine (T.D., Y.K., T. Noguchi, T. Nakashima, S.K., K. Nakao, M.F., T. Nagai, T.K., Y.T., Y.A., T.A., K.K., Y.G., S.Y.), Department of Pediatric Cardiology (E.T.), and Department of Statistics and Data Analysis, Center for Cerebral and Cardiovascular Disease Information (M.N., K.N.), National Cerebral and Cardiovascular Center, Suita, Japan; Department of Advanced Cardiovascular Medicine (T.D., S.Y.) and Department of Cardiovascular Medicine (H.S.), Tohoku
| | - Kengo Kusano
- From the Department of Cardiovascular Medicine (T.D., Y.K., T. Noguchi, T. Nakashima, S.K., K. Nakao, M.F., T. Nagai, T.K., Y.T., Y.A., T.A., K.K., Y.G., S.Y.), Department of Pediatric Cardiology (E.T.), and Department of Statistics and Data Analysis, Center for Cerebral and Cardiovascular Disease Information (M.N., K.N.), National Cerebral and Cardiovascular Center, Suita, Japan; Department of Advanced Cardiovascular Medicine (T.D., S.Y.) and Department of Cardiovascular Medicine (H.S.), Tohoku
| | - Hiroaki Shimokawa
- From the Department of Cardiovascular Medicine (T.D., Y.K., T. Noguchi, T. Nakashima, S.K., K. Nakao, M.F., T. Nagai, T.K., Y.T., Y.A., T.A., K.K., Y.G., S.Y.), Department of Pediatric Cardiology (E.T.), and Department of Statistics and Data Analysis, Center for Cerebral and Cardiovascular Disease Information (M.N., K.N.), National Cerebral and Cardiovascular Center, Suita, Japan; Department of Advanced Cardiovascular Medicine (T.D., S.Y.) and Department of Cardiovascular Medicine (H.S.), Tohoku
| | - Yoichi Goto
- From the Department of Cardiovascular Medicine (T.D., Y.K., T. Noguchi, T. Nakashima, S.K., K. Nakao, M.F., T. Nagai, T.K., Y.T., Y.A., T.A., K.K., Y.G., S.Y.), Department of Pediatric Cardiology (E.T.), and Department of Statistics and Data Analysis, Center for Cerebral and Cardiovascular Disease Information (M.N., K.N.), National Cerebral and Cardiovascular Center, Suita, Japan; Department of Advanced Cardiovascular Medicine (T.D., S.Y.) and Department of Cardiovascular Medicine (H.S.), Tohoku
| | - Satoshi Yasuda
- From the Department of Cardiovascular Medicine (T.D., Y.K., T. Noguchi, T. Nakashima, S.K., K. Nakao, M.F., T. Nagai, T.K., Y.T., Y.A., T.A., K.K., Y.G., S.Y.), Department of Pediatric Cardiology (E.T.), and Department of Statistics and Data Analysis, Center for Cerebral and Cardiovascular Disease Information (M.N., K.N.), National Cerebral and Cardiovascular Center, Suita, Japan; Department of Advanced Cardiovascular Medicine (T.D., S.Y.) and Department of Cardiovascular Medicine (H.S.), Tohoku
| |
Collapse
|
89
|
Matsubara N, Naito Y, Sasaki M, Yamamoto N, Takahashi S, Uemura H, Doi T. Phase I expansion cohort of TAS-115, a novel oral MET/VEGFR/FMS inhibitor, for castration-resistant prostate cancer patients (CRPC pts) with bone metastases. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx370.013] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
90
|
Takahashi S, Fujiwara Y, Matsubara N, Tomomatsu J, Iwasa S, Yamasaki A, Endo C, Yokoyama S, Doi T. Phase 1 study of ipatasertib (AKT inhibitor) for investigating safety, tolerability, pharmacokinetics (PK), efficacy, and biomarkers in Japanese patients (pts) with solid tumors including castration-resistant prostate cancer (CRPC). Ann Oncol 2017. [DOI: 10.1093/annonc/mdx367.028] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
91
|
Kurokawa Y, Doi T, Sawaki A, Komatsu Y, Ozaka M, Takahashi T, Naito Y, Okubo S, Nishida T. Phase II study of TAS-116, an oral inhibitor of heat shock protein 90 (HSP90), in metastatic or unresectable gastrointestinal stromal tumor refractory to imatinib, sunitinib and regorafenib. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx387.006] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
92
|
Mehnert J, Rugo H, O'Neil B, Santoro A, Schellens J, Cohen R, Doi T, Ott P, Pishvaian M, Puzanov I, Aung K, Hsu C, Le Tourneau C, Soria JC, Elez E, Tamura K, Gould M, Zhao G, Stein K, Piha-Paul S. Pembrolizumab for patients with PD-L1–positive advanced carcinoid or pancreatic neuroendocrine tumors: Results from the KEYNOTE-028 study. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx368] [Citation(s) in RCA: 37] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
93
|
Ott P, Bang YJ, Razak A, Bennouna J, Soria JC, Rugo H, Cohen R, O'Neil B, Mehnert J, Lopez J, Doi T, van Brummelen E, Levitan D, Zhao G, Emancipator K, Stein K, Joe A, Ayers M, Lunceford J, Piha-Paul S. Relationship of PD-L1 and a T-cell inflamed gene expression profile (GEP) to clinical response in a multicohort trial of solid tumors (KEYNOTE [KN]028). Ann Oncol 2017. [DOI: 10.1093/annonc/mdx363] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
94
|
Kuboki Y, Matsubara N, Bando H, Shitara K, Yoh K, Kojima T, Ohno I, Takahashi H, Harano K, Kondo S, Hirai H, Morizane C, Doi T. First-in-human (FIH) study of TAS-120, a highly selective covalent oral fibroblast growth factor receptor (FGFR) inhibitor, in patients (pts) with advanced solid tumors. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx367.006] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
95
|
Hamid O, Ros W, Thompson J, Hu-Lieskovan S, Eskens F, Diab A, Doi T, Wasser J, Spano JP, Rizvi N, Angevin E, Chiappori A, Ott P, Ganguly B, Fleener C, Dell V, Liao K, Joh T, Chou J, El-Khoueiry A. Safety, pharmacokinetics (PK) and pharmacodynamics (PD) data from a phase I dose-escalation study of OX40 agonistic monoclonal antibody (mAb) PF-04518600 (PF-8600) in combination with utomilumab, a 4-1BB agonistic mAb. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx376.008] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
96
|
Yamamoto N, Muro K, Ishii H, Kato T, Tsushima T, Takenoyama M, Oizumi S, Kawakami T, Doi T. Anti-CC-chemokine receptor 4 (CCR4) antibody mogamulizumab (Moga) and nivolumab (Nivo) combination phase I study in patients with advanced or metastatic solid tumors. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx440.010] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
97
|
Tsurutani J, Doi T, Iwata H, Takahashi S, Modi S, Tamura K, Shitara K, Taniguchi H, Taira S, Li B, Shimomura A, Sato Y, Akiyama K, Fujisaki Y, Lee C, Yver A, Nakagawa K. Updated results of phase 1 study of DS-8201a in patients with HER2 expressing non-breast, non-gastric malignancies. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx367.042] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
98
|
Yamazaki K, Kuboki Y, Shinozaki E, Hara H, Komatsu Y, Nishina T, Yamaguchi K, Yuki S, Bando H, Asayama M, Tsushima T, Hamauchi S, Nakatsumi H, Kajiwara T, Wakabayashi M, Nomura S, Sato A, Doi T, Ohtsu A, Yoshino T. A Multicentre Phase I/II Study of TAS-102 with nintedanib in patients with metastatic colorectal cancer refractory to standard therapies (N-task force: EPOC1410). Ann Oncol 2017. [DOI: 10.1093/annonc/mdx393.042] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
99
|
Wainberg Z, Jalal S, Muro K, Yoon H, Garrido M, Golan T, Doi T, Catenacci D, Geva R, Ku G, Bleeker J, Bang YJ, Hara H, Chung H, Savage M, Wang J, Koshiji M, Dalal R, Fuchs C. KEYNOTE-059 Update: Efficacy and safety of pembrolizumab alone or in combination with chemotherapy in patients with advanced gastric or gastroesophageal (G/GEJ) cancer. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx440.020] [Citation(s) in RCA: 22] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022] Open
|
100
|
Doi T, Kataoka Y, Asaumi Y, Hori M, Nishikawa R, Tsuda K, Ogura M, Noguchi T, Harada-Shiba M, Yasuda S. P631Sex-related differences in clinical characteristics, low-density lipoprotein cholesterol control and cardiovascular outcomes in familial hypercholesterolemia. Eur Heart J 2017. [DOI: 10.1093/eurheartj/ehx501.p631] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|